Heidi Cuthbert

Ondo Finance (CRYPTO:ONDO) has launched an in-kind conversion mechanism to let approved institutions mint tokenised equities using shares they already hold.

Genetic Signatures (ASX:GSS) has agreed on commercial terms to acquire Microba Life Sciences (ASX:MAP).

An Australian Senate committee has recommended that the federal government consider nationalising the national emergency call system operated by Telstra (ASX:TLS).

ADARx Pharmaceuticals announced plans to pursue a U.S. initial public offering that could value the rare disease-focused biotechnology company at up to approximately $1.74 billion.

NewAmsterdam Pharma (NASDAQ:NAMS) and partner Menarini Group announced that the European Commission has granted marketing authorization for Ubeslo® (10 mg obicetrapib monotherapy) and Evlarco® (10 mg obicetrapib plus 10 mg ezetimibe).

Johnson & Johnson (NYSE:JNJ) announced positive topline results from a pivotal Phase 3 trial evaluating CAPLYTA® (lumateperone) 42 mg once daily for the treatment of acute manic episodes in adults with bipolar I disorder.

Helus Pharma (NASDAQ:HELP) presented four posters on its investigational oral deuterated psilocin analog HLP003 for major depressive disorder (MDD) at Psych Congress 2026 in New Orleans.

Insmed (NASDAQ:INSM) received FDA Priority Review for its supplemental New Drug Application seeking full approval of ARIKAYCE (amikacin liposome inhalation suspension) for treating Mycobacterium avium complex (MAC) lung disease.

Novo Nordisk (NYSE:NVO) reported phase 3 topline results showing once-weekly CagriSema achieved weight loss and blood sugar reductions in adults with type 2 diabetes and obesity.

Accenture (NYSE:ACN) shares rose after the company announced a partnership with AI lab Anthropic to support artificial intelligence model evaluation and testing.